Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen Inc. (NASDAQ: OCGN ) is a clinical-stage biotechnology company developing an interesting pipeline of modifier gene therapies for rare inherited retinal diseases. In particular, their focus is on those diseases that cause progressive vision lossMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busi ...